Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum Resistant High Grade Serous Ovarian Cancer”

50 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 50 results

Early research (Phase 1)Ended earlyNCT01227941
What this trial is testing

MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)

Who this might be right for
Ovarian Cancer
Tesaro, Inc. 6
Testing effectiveness (Phase 2)Ended earlyNCT03311334
What this trial is testing

DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Who this might be right for
Renal Cell Carcinoma (RCC)Urothelial CarcinomaPrimary Peritoneal Cancer+3 more
Sumitomo Pharma America, Inc. 47
Early research (Phase 1)Ended earlyNCT04893551
What this trial is testing

Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants

Who this might be right for
Ovarian Neoplasms
BerGenBio ASA 16
Testing effectiveness (Phase 2)WithdrawnNCT06393751
What this trial is testing

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+20 more
National Cancer Institute (NCI)
Early research (Phase 1)Looking for participantsNCT05950464
What this trial is testing

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Who this might be right for
Recurrent Endometrial CarcinomaRecurrent Endometrial Clear Cell AdenocarcinomaRecurrent Endometrial Endometrioid Adenocarcinoma+6 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Looking for participantsNCT05998135
What this trial is testing

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Who this might be right for
Ovarian High Grade Serous AdenocarcinomaPlatinum-Resistant Ovarian Carcinoma
Emory University 28
Testing effectiveness (Phase 2)Looking for participantsNCT05551507
What this trial is testing

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
InxMed (Shanghai) Co., Ltd. 150
Large-scale testing (Phase 3)Active Not RecruitingNCT02839707
What this trial is testing

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube High Grade Serous AdenocarcinomaOvarian High Grade Serous AdenocarcinomaOvarian Seromucinous Carcinoma+16 more
National Cancer Institute (NCI) 444
Early research (Phase 1)Looking for participantsNCT06799065
What this trial is testing

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Who this might be right for
Advanced Solid TumorsBreast Cancer RecurrentOvarian Cancer+2 more
Accent Therapeutics 90
Testing effectiveness (Phase 2)Looking for participantsNCT05128825
What this trial is testing

Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc 170
Testing effectiveness (Phase 2)Active Not RecruitingNCT03587311
What this trial is testing

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaOvarian Endometrioid Adenocarcinoma+5 more
National Cancer Institute (NCI) 96
Large-scale testing (Phase 3)Looking for participantsNCT05281471
What this trial is testing

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Who this might be right for
Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerFallopian Tube Cancer+4 more
Genelux Corporation 186
Testing effectiveness (Phase 2)Looking for participantsNCT04918186
What this trial is testing

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Who this might be right for
Ovarian Cancer
Canadian Cancer Trials Group 60
Early research (Phase 1)Ended earlyNCT03608618
What this trial is testing

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Who this might be right for
Peritoneal MesotheliomaFallopian Tube AdenocarcinomaAdenocarcinoma of the Ovary+1 more
MaxCyte, Inc. 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT05446298
What this trial is testing

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal Carcinoma+1 more
OncoC4, Inc. 58
Testing effectiveness (Phase 2)WithdrawnNCT03933761
What this trial is testing

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

Who this might be right for
Ovarian CancerCarcinosarcoma
Australia New Zealand Gynaecological Oncology Group
Early research (Phase 1)Active Not RecruitingNCT04616534
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Who this might be right for
Advanced Fallopian Tube CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma+19 more
National Cancer Institute (NCI) 14
Early research (Phase 1)Ended earlyNCT03924245
What this trial is testing

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Who this might be right for
Fallopian Tube CancerFallopian Tube CarcinosarcomaFallopian Tube Clear Cell Adenocarcinoma+10 more
Vanderbilt-Ingram Cancer Center 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Early research (Phase 1)Active Not RecruitingNCT03586661
What this trial is testing

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial Adenocarcinoma+8 more
M.D. Anderson Cancer Center 31
Load More Results